�鶹��ýӰ��

Meeting Coverage >

EULAR

Novel IL-17 Inhibitor Passes Mid-Stage Test in Psoriatic Arthritis

Phase II results suggest drug could outperform existing agents

Trial Upends Guidelines on Long-Term Steroids in Rheumatoid Arthritis

Vindication for clinicians who ignored official recommendations

European Docs See Smooth Post-COVID Future in Rheumatology

Many long-term impacts inevitable, but EULAR attendees mostly optimistic

Sex and the (Not Quite) Single Arthritis Patient

It isn't good for many

Can Methotrexate Treat Arthritis Before It Becomes Arthritis?

Mainstay drug for RA helpful in disease's earliest stage

Air Pollution and Illness: It's Not Just the Lungs and Heart Anymore

Expanding range of conditions caused or aggravated by fine particulates

Secukinumab Shows Promise for Kids With Arthritis

More than 90% responded at week 12, study showed

COVID Vaccine Safe in Rheumatic Patients

Few disease flares and only two serious adverse events thus far in EULAR registry

Targeting GM-CSF: A New Approach to COVID?

Risk of death was reduced by 61% in global phase II trial of mavrilimumab

Personalized Algorithm Helps Guide Rituximab Retreatment

For ANCA-associated vasculitis, fixed retreatment not needed if naive B cells reappear

Guselkumab Succeeds for TNF Failures in Psoriatic Arthritis

Benefits seen across all domains in phase IIIb trial

IVIG a Winner for Dermatomyositis

Pivotal phase III trial shows clear efficacy

Nintedanib Slows Decline in RA-Associated Interstitial Lung Disease

Similar results to original larger trial seen in post-hoc analysis

Oral JAK 1 Inhibitor Eases Spine Inflammation in Ankylosing Spondylitis

Treatment with filgotinib resulted in significant improvements compared with placebo

Even Exposure to Passive Smoking Increases Risk of RA

Disease onset was earlier in women exposed to smoky rooms during childhood

Rituximab a Hazard in RA Patients With COVID

Poor outcomes were fourfold higher among rituximab users than for those on TNF inhibitors

Gout: Methotrexate May Enhance Pegloticase Response

In small study, uric acid levels were reduced to near undetectable levels in almost 80% of patients

Psoriatic Arthritis: Outcomes Similar for Cosentyx and Humira

Primary endpoint of superiority for secukinumab over adalimumab not met in a phase IIIb trial

Voclosporin Beats Standard of Care in Lupus Nephritis

High rates of response seen even among difficult-to-treat Hispanic patients

Rheumatoid Arthritis: Remission Rates High With Very Early Tx

Highest rates at 6 months seen with abatacept plus methotrexate

Avacopan Superior to Steroids in ANCA Vasculitis

Greater rates of remission and improved renal function seen with oral C5a receptor antagonist

Another IL-6 Blocker Succeeds in Rheumatoid Arthritis

Effective in patients with moderately to severely active disease in a phase III trial

EULAR 2020: What to Expect

Cancelled due to pandemic but extensive menu of virtual learning planned

Methotrexate Withdrawal: Feasible in Stable RA?

Tofacitinib monotherapy appears to maintain low disease activity

IL-17a Drug Rescues Many Refractory Psoriatic Arthritis Cases

Disease abated in half of patients receiving secukinumab after failing other biologics

No Cancer Risk Found With TNF Inhibitors in Psoriatic Arthritis

Expected cancer cases similar to those in general populace, study shows

Low-Dose Steroid Reduces Hand Pain in Osteoarthritis

Finger pain relieved at 6 weeks with prednisolone therapy

Sjogren's Oral Drug Fails in Small Trial

More than half of patients developed rashes

Cardiovascular Risk in RA: Beyond Inflammation?

With adverse lifestyle plus bad genes plus inflammation, 'you unleash hell'

Weight, Smoking Inhibit RA Remission

Factors differ for women and men, but both relate to lifestyle

Meds Improve Cardiovascular Risk in RA

Benefits seen for hydroxychloroquine, methotrexate, and tocilizumab

Tofacitinib Shows MRI Benefits in AS

Improvements seen on MRI for both sacroiliac joints and spine

Remission Common in Early SpA With Golimumab

Drug-free remission maintained for more than half after at least 12 months

Stelara Eases Spine Symptoms in PsA

Improvements with ustekinumab maintained for 2 years

Heart Risk Higher in Sjogren's Patients

PARIS -- Patients with Sjogren's syndrome had more than double the heart attack risk seen in the general population, a researcher reported here.

Orencia Combo Tops in Early, Severe RA

PARIS -- In a study of patients with poor-prognosis early rheumatoid arthritis, more patients treated with abatacept (Orencia) plus methotrexate were in remission at 1 year than were those on methotrexate alone, a researcher reported here.